For individuals with type 1 diabetes (T1D), pharmaceutical developments in modern ultra-long acting basal insulins with refined pharmacokinetic and pharmacodynamic profiles have led to improved glycaemic outcomes (4–10). The gene discussed is INS; the disease is type 1 diabetes mellitus.